Nordic healthcare and biotech growth capital investor KDev Investments, jointly owned by Karolinska Development and Rosetta Capital, has sold its stake in Swedish pharmaceutical research business Inhalation Sciences to Råsunda Förvaltning.
Deal ends a five-year stint under Foresight ownership, which first invested in 2013
Trevi appointed a chief restructuring officer in 2017 to negotiate a debt restructuring plan
AI business will look to expand beyond marketing and into robotics, healthcare and education
Company's founders and CEO Klaus Schmidt have retained a significant minority stake